SBP 101

Drug Profile

SBP 101

Alternative Names: SBP-101; SUN 101

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Florida
  • Developer Sun BioPharma
  • Class Antineoplastics; Polyamines
  • Mechanism of Action Apoptosis stimulants; Caspase 3 stimulants; Cell division inhibitors; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer
  • Preclinical Pancreatitis

Most Recent Events

  • 14 Nov 2017 Updated efficacy data from a phase Ia dose-escalation trial in Pancreatic cancer released by Sun BioPharma
  • 04 Oct 2017 Updated efficacy data from a phase Ia/Ib trial in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) released by Sun BioPharma
  • 04 Oct 2017 Sun BioPharma plans a clinical trial for Pancreatic cancer (Metastatic disease, Combination therapy, First-line therapy) in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top